Monoclonal Antibody Therapy of Mouse Leukemia

Specific Selection of Host Cell Glycoproteins during Assembly of Murine Leukaemia Virus and Vesicular Stomatitis Virus: Presence of Thy-1 Glycoprotein and Absence of H-2, Pgp-1 and T-200 Glycoproteins on the Envelopes of these Virus Particles

“…Three of these antibodies detected determinants on the Thy-1 molecule. The same phenomena on the KKT-2 cells were found by these authors with monoclonal antibody 19-XE5 prepared by Dr M. E. Lostrom, which precipitates a 27 000 dalton protein similar to the protein precipitated by antibody 19-E12 used in this paper and also provided by Dr Lostrom (Bernstein et al, 1980). Therefore, we can conclude that with monoclonal antibody 19-E12 we detected a Thy-1.1 molecule on the BW5 cell line (also an AKR mouse T lymphoma) that can be a viral receptor for a leukaemogenic MuLV.…”

“…Monoclonal antibody 19-E12 (Bernstein et al, 1980) was kindly provided by Dr M. E. Lostrom. The gps detected by these monoclonal antibodies are described in Tables 1 and 2.…”

Treatment of Malignancy with Unmodified Antibody

“…In studies using IgG2a anti-Thy 1.1 antibody to treat the AKR/J mice shortly after implantation of SL-2 T-cell lymphoma cells [21][22][23][24], rela tively large doses of 3.2 mg/animal were required for the maximal antitumor effect [24]. Following infusion of these doses of antibody, up to 84% of animals implanted with 3 X 10s lymphoma cells were cured, while infusion of either lower (0.2-0.4 mg) or higher doses (6.4-18 mg/animal) resulted in decreased cure rates.…”

“…A variety of human malignancies have been treated, including leukemia and lymphoma [2][3][4][5][6][7][8][9][10][11][12][13][14], melanoma [15][16][17], neuroblastoma [15] and colon car cinoma [18][19][20], While the results of these clinical studies have demonstrated that monoclonal antibodies can have an antitu mor effect, significant tumor responses have occurred in a minority of patients and have been generally short-lived. Studies in experi mental animals have shown that passively infused antibody can cure animals if admin istered shortly after challenge with a rela tively small number of transplanted tumor 1 Supported by NIH grants CA 39675, CA 09351, CA 18029 and CA 26386. cells [21][22][23][24][25][26][27], but cannot cure animals chal lenged with a larger number of tumor cells or animals with established disease [24][25][26][27], While these studies have suggested that unmodified antibody will not have wide spread clinical utility, they have identified many factors that influence the success of antibody therapy, and have elucidated the mechanisms by which passively infused anti body leads to tumor regression. In this pa per, we review studies of antitumor therapy employing unmodified antibodies in experi mental animals, which have formed the basis for more recent efforts to overcome the lim itations of unmodified antibody.…”

IgM response and resistance to ascites tumor growth

“…However, some IgM monoclonal antibodies inhibiting tumor growth in different tumor systems have been described [1,8]. Also, the regression of a human lung carcinoma has been associated with the presence of a monoclonal IgM macroglobulin recognizing tumor cell surface components [9].…”